Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
When Pfizer bought dalbavancin and anidulofungin from Vicuron in 2005, it shelled out USD 1.9 billion for both Phase 3 drugs. One can argue whether each drugs had the same commercial value for Pfizer but it is safe to assume that dalbavancin was valued at approx. USD 1 billion at Continue reading Dalbavancin Sale to Actavis
Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections. Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to control. Only for Candida several good treatments exist on the Continue reading Nikkomycins Are Finally Getting Some Respect
For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down: 31 compounds with QIDP designation 29 antibacterials, 2 antifungals 22 systemically active, 9 for topical administration 13 in Phase 3, 9 in Phase Continue reading QIDP Drugs: Here They Are, All of Them